Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Quansheng Biotechnology is a biotechnology company based in Shanghai, China, specializing in the development and production of innovative cell therapies. The company operates a GMP-compliant laboratory dedicated to the extraction, culture, and expansion of human umbilical cord mesenchymal stem cells (hUC-MSCs). Its research focus is primarily on immune-mediated and inflammatory conditions, with active preclinical programs targeting ischemic stroke, acute liver failure, and psoriasis. In addition to its internal drug development pipeline, the company provides high-purity stem cell products and experimental instruments to support academic and clinical research collaborations. Shanghai Quansheng aims to leverage its cell therapy platform to address significant unmet medical needs in regenerative medicine and immunology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanghai Quan Sheng Biotechnology.